Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN.
Department of Pathology and Laboratory Medicine, New Jersey Medical School, The State University of New Jersey, Rutgers, Newark, NJ.
Hepatology. 2019 Feb;69(2):639-652. doi: 10.1002/hep.30211. Epub 2019 Jan 5.
Disruption of epigenetic mechanisms has been intimately linked to the etiology of human cancer. Understanding how these epigenetic mechanisms (including DNA methylation [5mC], hydroxymethylation [5hmC], and histone post-translational modifications) work in concert to drive cancer initiation and progression remains unknown. Hepatocellular carcinoma (HCC) is increasing in frequency in Western countries but lacks efficacious treatments. The epigenome of HCC remains understudied. To better understand the epigenetic underpinnings of HCC, we performed a genome-wide assessment of 5mC, 5hmC, four histone modifications linked to promoter/enhancer function (H3K4me1, H3K27ac, H3K4me3, and H3K27me3), and transcription across normal, cirrhotic, and HCC liver tissue. Implementation of bioinformatic strategies integrated these epigenetic marks with each other and with transcription to provide a comprehensive epigenetic profile of how and when the liver epigenome is perturbed during progression to HCC. Our data demonstrate significant deregulation of epigenetic regulators combined with disruptions in the epigenome hallmarked by profound loss of 5hmC, locus-specific gains in 5mC and 5hmC, and markedly altered histone modification profiles, particularly remodeling of enhancers. Data integration demonstrates that these marks collaborate to influence transcription (e.g., hyper-5hmC in HCC-gained active enhancers is linked to elevated expression) of genes regulating HCC proliferation. Two such putative epigenetic driver loci identified through our integrative approach, COMT and FMO3, increase apoptosis and decrease cell viability in liver-derived cancer cell lines when ectopically re-expressed. Conclusion: Altogether, integration of multiple epigenetic parameters is a powerful tool for identifying epigenetically regulated drivers of HCC and elucidating how epigenome deregulation contributes to liver disease and HCC.
表观遗传机制的破坏与人类癌症的病因密切相关。了解这些表观遗传机制(包括 DNA 甲基化[5mC]、羟甲基化[5hmC]和组蛋白翻译后修饰)如何协同作用以驱动癌症的发生和进展仍然未知。肝细胞癌(HCC)在西方国家的发病率正在增加,但缺乏有效的治疗方法。HCC 的表观基因组仍未得到充分研究。为了更好地理解 HCC 的表观遗传基础,我们对正常、肝硬化和 HCC 肝组织中的 5mC、5hmC、与启动子/增强子功能相关的四种组蛋白修饰(H3K4me1、H3K27ac、H3K4me3 和 H3K27me3)以及转录进行了全基因组评估。生物信息学策略的实施将这些表观遗传标记与彼此以及与转录相结合,提供了肝表观基因组在向 HCC 进展过程中如何以及何时受到干扰的综合表观遗传谱。我们的数据表明,表观遗传调节剂的显著失调与表观基因组的破坏相结合,其特征是 5hmC 的深度丧失、5mC 和 5hmC 的局部获得以及明显改变的组蛋白修饰谱,特别是增强子的重塑。数据集成表明,这些标记协同作用影响调节 HCC 增殖的基因的转录(例如,HCC 中获得的高 5hmC 的活跃增强子与升高的表达相关)。通过我们的综合方法确定的两个假定的表观遗传驱动基因座,COMT 和 FMO3,当异位重新表达时,可增加肝源性癌细胞系中的细胞凋亡并降低细胞活力。结论:总之,整合多个表观遗传参数是识别 HCC 中受表观遗传调控的驱动因素并阐明表观基因组失调如何导致肝病和 HCC 的有力工具。